IPS cell modeling of cardiometabolic diseases

Journal of Cardiovascular Translational Research

Volumn 6, Issue 1, 2013, Pages 46-53

  Nakamura, Kenta ^a   Hirano, Ken Ichi ^b   Wu, Sean M ^a,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b OSAKA UNIVERSITY   (Japan)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Cardiometabolic disease; Disease modeling; Induced pluripotent stem cell; Storage disease

Indexed keywords

ADIPOSE TRIGLYCERIDE LIPASE; ALPHA GALACTOSIDASE; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUCOSE 6 PHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; X LINKED LYSOSOMAL HYDROLASE ALPHA GALACTOSIDASE A;

ARTICLE; CARDIOMETABOLIC DISEASE; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; DANON DISEASE; DISEASE ASSOCIATION; DISEASE MODEL; DYSLIPIDEMIA; FABRY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; GLYCOGEN STORAGE DISEASE TYPE 1; GLYCOGEN STORAGE DISEASE TYPE 2; HEART DISEASE; HEART MUSCLE CELL; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE METABOLISM; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIPIDOSIS; METABOLIC DISORDER; NEUTRAL LIPID STORAGE DISEASE; OBESITY; PATHOPHYSIOLOGY; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELLS, CULTURED; GLYCOGEN STORAGE DISEASE TYPE II; GLYCOGEN STORAGE DISEASE TYPE IIB; HEART DISEASES; HUMANS; ICHTHYOSIFORM ERYTHRODERMA, CONGENITAL; INDUCED PLURIPOTENT STEM CELLS; LIPID METABOLISM, INBORN ERRORS; METABOLIC DISEASES; MUSCULAR DISEASES; MYOCYTES, CARDIAC; PHENOTYPE;

IPS;

EID: 84872595125     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-012-9413-4     Document Type: Article

References (74)

1. Evans, M. J; & Kaufman, M. H. (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature, 292(5819), 154-156. (Pubitemid 11050741)
2. Thomson, J. A; Itskovitz-Eldor, J; Shapiro, S. S; Waknitz, M. A; Swiergiel, J. J; Marshall, V. S; et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282(5391), 1145-1147. (Pubitemid 28516247)
3. Robinton, D. A; & Daley, G. Q. (2012). The promise of induced pluripotent stem cells in research and therapy. Nature, 481(7381), 295-305. doi: 10.1038/nature10761.
4. Takahashi, K; & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663-676. doi: 10.1016/j.cell.2006.07.024. (Pubitemid 44233629)
5. Takahashi, K; Tanabe, K; Ohnuki, M; Narita, M; Ichisaka, T; Tomoda, K; et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861-872. doi: 10.1016/j.cell.2007.11.019. (Pubitemid 350138099)
6. Reaven, G. M. (1988). Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 37(12), 1595-1607. (Pubitemid 19004941)
7. Lakka, H. M; Laaksonen, D. E; Lakka, T. A; Niskanen, L. K; Kumpusalo, E; Tuomilehto, J; et al. (2002). The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA: The Journal of the American Medical Association, 288(21), 2709-2716. (Pubitemid 35403784)
8. Haffner, S. M; Lehto, S; Ronnemaa, T; Pyorala, K; & Laakso, M. (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. The New England Journal of Medicine, 339(4), 229-234. doi: 10.1056/ NEJM199807233390404. (Pubitemid 28350165)
9. Malik, S; Wong, N. D; Franklin, S. S; Kamath, T. V; L'Italien, G. J; Pio, J. R; et al. (2004). Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation, 110(10), 1245-1250. doi: 10.1161/01.CIR.0000140677.20606. 0E. (Pubitemid 39202340)
10. Park, I. H; Arora, N; Huo, H; Maherali, N; Ahfeldt, T; Shimamura, A; et al. (2008). Disease-specific induced pluripotent stem cells. Cell, 134(5), 877-886. doi: 10.1016/j.cell.2008.07.041.
11. Maehr, R; Chen, S; Snitow, M; Ludwig, T; Yagasaki, L; Goland, R; et al. (2009). Generation of pluripotent stem cells from patients with type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America, 106(37), 15768-15773. doi: 10.1073/pnas.0906894106.
12. Murry, C. E; & Keller, G. (2008). Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell, 132(4), 661-680. doi: 10.1016/j.cell.2008.02.008. (Pubitemid 351260059)
13. Meyer, J. S; Shearer, R. L; Capowski, E. E; Wright, L. S; Wallace, K. A; McMillan, E. L; et al. (2009). Modeling early retinal development with human embryonic and induced pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, 106(39), 16698-16703. doi: 10.1073/pnas.0905245106.
14. Hu, B. Y; Weick, J. P; Yu, J; Ma, L. X; Zhang, X. Q; Thomson, J. A; et al. (2010). Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proceedings of the National Academy of Sciences of the United States of America, 107(9), 4335-4340. doi: 10.1073/pnas.0910012107.
15. Kim, K; Doi, A; Wen, B; Ng, K; Zhao, R; Cahan, P; et al. (2010). Epigenetic memory in induced pluripotent stem cells. Nature, 467(7313), 285-290. doi: 10.1038/nature09342.
16. Polo, J. M; Liu, S; Figueroa, M. E; Kulalert, W; Eminli, S; Tan, K. Y; et al. (2010). Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nature Biotechnology, 28(8), 848-855. doi: 10.1038/nbt.1667.
17. Osafune, K; Caron, L; Borowiak, M; Martinez, R. J; Fitz-Gerald, C. S; Sato, Y; et al. (2008). Marked differences in differentiation propensity among human embryonic stem cell lines. Nature Biotechnology, 26(3), 313-315. doi: 10.1038/nbt1383. (Pubitemid 351355125)
18. Nguyen, H. N; Byers, B; Cord, B; Shcheglovitov, A; Byrne, J; Gujar, P; et al. (2011). LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell, 8(3), 267-280. doi: 10.1016/j.stem.2011.01.013.
19. Brennand, K. J; Simone, A; Jou, J; Gelboin-Burkhart, C; Tran, N; Sangar, S; et al. (2011). Modelling schizophrenia using human induced pluripotent stem cells. Nature, 473(7346), 221-225. doi: 10.1038/nature09915.
20. Cao, N; Liu, Z; Chen, Z; Wang, J; Chen, T; Zhao, X; et al. (2012). Ascorbic acid enhances the cardiac differentiation of induced pluripotent stem cells through promoting the proliferation of cardiac progenitor cells. Cell Research, 22(1), 219-236. doi: 10.1038/cr.2011.195.
21. Beqqali, A; Kloots, J; Ward-van Oostwaard, D; Mummery, C; & Passier, R. (2006). Genome-wide transcriptional profiling of human embryonic stem cells differentiating to cardiomyocytes. Stem Cells, 24(8), 1956-1967. doi: 10.1634/stemcells.2006-0054. (Pubitemid 44474172)
22. Davis, R. P; van den Berg, C. W; Casini, S; Braam, S. R; & Mummery, C. L. (2011). Pluripotent stem cell models of cardiac disease and their implication for drug discovery and development. Trends in Molecular Medicine, 17(9), 475-484. doi: 10.1016/j.molmed.2011.05.001.
23. Itzhaki, I; Rapoport, S; Huber, I; Mizrahi, I; Zwi-Dantsis, L; Arbel, G; et al. (2011). Calcium handling in human induced pluripotent stem cell derived cardiomyocytes. PloS One, 6(4), e18037. doi: 10.1371/journal.pone.0018037.
24. Qiu, C; Olivier, E. N; Velho, M; & Bouhassira, E. E. (2008). Globin switches in yolk sac-like primitive and fetal-like definitive red blood cells produced from human embryonic stem cells. Blood, 111(4), 2400-2408. doi: 10.1182/blood-2007-07-102087. (Pubitemid 351451453)
25. Kroon, E; Martinson, L. A; Kadoya, K; Bang, A. G; Kelly, O. G; Eliazer, S; et al. (2008). Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nature Biotechnology, 26(4), 443-452. doi: 10.1038/nbt1393. (Pubitemid 351501814)
26. Park, T. S; Zimmerlin, L; & Zambidis, E. T. (2012). Efficient and simultaneous generation of hematopoietic and vascular progenitors from human induced pluripotent stem cells. Cytometry Part A: The Journal of the International Society for Analytical Cytology. doi: 10.1002/cyto.a.22090.
27. Li, Z; Hu, S; Ghosh, Z; Han, Z; & Wu, J. C. (2011). Functional characterization and expression profiling of human induced pluripotent stem cell- and embryonic stem cell-derived endothelial cells. Stem Cells and Development, 20(10), 1701-1710. doi: 10.1089/scd.2010.0426.
28. Drukker, M; Tang, C; Ardehali, R; Rinkevich, Y; Seita, J; Lee, A. S; et al. (2012). Isolation of primitive endoderm, mesoderm, vascular endothelial and trophoblast progenitors from human pluripotent stem cells. Nature Biotechnology, 30(6), 531-542. doi: 10.1038/nbt.2239.
29. Dimos, J. T; Rodolfa, K. T; Niakan, K. K; Weisenthal, L. M; Mitsumoto, H; Chung, W; et al. (2008). Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science, 321(5893), 1218-1221. doi: 10.1126/science.1158799.
30. Keller, G. (2005). Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes & Development, 19(10), 1129-1155. doi: 10.1101/gad.1303605. (Pubitemid 40696181)
31. Chambers, S. M; Fasano, C. A; Papapetrou, E. P; Tomishima, M; Sadelain, M; & Studer, L. (2009). Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nature Biotechnology, 27(3), 275-280. doi: 10.1038/nbt.1529.
32. Soldner, F; Hockemeyer, D; Beard, C; Gao, Q; Bell, G. W; Cook, E. G; et al. (2009). Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell, 136(5), 964-977. doi: 10.1016/j.cell.2009.02.013.
33. Itskovitz-Eldor, J; Schuldiner, M; Karsenti, D; Eden, A; Yanuka, O; Amit, M; et al. (2000). Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Molecular Medicine, 6(2), 88-95.
34. Martin, G. R; & Evans, M. J. (1975). Differentiation of clonal lines of teratocarcinoma cells: formation of embryoid bodies in vitro. Proceedings of the National Academy of Sciences of the United States of America, 72(4), 1441-1445.
35. Logan, C. Y; & Nusse, R. (2004). The Wnt signaling pathway in development and disease. Annual Review of Cell and Developmental Biology, 20, 781-810. doi: 10.1146/annurev.cellbio.20.010403.113126. (Pubitemid 39488658)
36. Schier, A. F. (2003). Nodal signaling in vertebrate development. Annual Review of Cell and Developmental Biology, 19, 589-621. doi: 10.1146/annurev. cellbio.19.041603.094522. (Pubitemid 37487362)
37. Niswander, L; & Martin, G. R. (1992). Fgf-4 expression during gastrulation, myogenesis, limb and tooth development in the mouse. Development, 114(3), 755-768.
38. Burridge, P. W; Keller, G; Gold, J. D; & Wu, J. C. (2012). Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell, 10(1), 16-28. doi: 10.1016/j.stem.2011.12. 013.
39. Willems, E; Bushway, P. J; & Mercola, M. (2009). Natural and synthetic regulators of embryonic stem cell cardiogenesis. Pediatric Cardiology, 30(5), 635-642. doi: 10.1007/s00246-009-9409-2.
40. Huber, I; Itzhaki, I; Caspi, O; Arbel, G; Tzukerman, M; Gepstein, A; et al. (2007). Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 21(10), 2551-2563. doi: 10.1096/fj.05-5711com. (Pubitemid 47230684)
41. Kita-Matsuo, H; Barcova, M; Prigozhina, N; Salomonis, N; Wei, K; Jacot, J. G; et al. (2009). Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes. PloS One, 4(4), e5046. doi: 10.1371/journal.pone.0005046.
42. Sachdev, B; Takenaka, T; Teraguchi, H; Tei, C; Lee, P; McKenna, W. J; et al. (2002). Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation, 105(12), 1407-1411. (Pubitemid 34263268)
43. Arad, M; Maron, B. J; Gorham, J. M; Johnson, W. H; Jr; Saul, J. P; Perez-Atayde, A. R; et al. (2005). Glycogen storage diseases presenting as hypertrophic cardiomyopathy. The New England Journal of Medicine, 352(4), 362-372. doi: 10.1056/NEJMoa033349.
44. Van den Hout, H; Reuser, A. J; Vulto, A. G; Loonen, M. C; Cromme-Dijkhuis, A; & Van der Ploeg, A. T. (2000). Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet, 356(9227), 397-398. (Pubitemid 30487498)
45. Nakao, S; Takenaka, T; Maeda, M; Kodama, C; Tanaka, A; Tahara, M; et al. (1995). An atypical variant of Fabry's disease in men with left ventricular hypertrophy. The New England Journal of Medicine, 333(5), 288-293. doi: 10.1056/NEJM199508033330504.
46. Danon, M. J; Oh, S. J; DiMauro, S; Manaligod, J. R; Eastwood, A; Naidu, S; et al. (1981). Lysosomal glycogen storage disease with normal acid maltase. Neurology, 31(1), 51-57. (Pubitemid 11217453)
47. Nishino, I; Fu, J; Tanji, K; Yamada, T; Shimojo, S; Koori, T; et al. (2000). Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature, 406(6798), 906-910. doi: 10.1038/35022604. (Pubitemid 30664268)
48. Rashid, S. T; Corbineau, S; Hannan, N; Marciniak, S. J; Miranda, E; Alexander, G; et al. (2010). Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. The Journal of Clinical Investigation, 120(9), 3127-3136. doi: 10.1172/JCI43122.
49. Bernier, A. V; Correia, C. E; Haller, M. J; Theriaque, D. W; Shuster, J. J; & Weinstein, D. A. (2009). Vascular dysfunction in glycogen storage disease type I. The Journal of Pediatrics, 154(4), 588-591. doi: 10.1016/j.jpeds.2008.10.048.
50. Lee, P. J; Celermajer, D. S; Robinson, J; McCarthy, S. N; Betteridge, D. J; & Leonard, J. V. (1994). Hyperlipidaemia does not impair vascular endothelial function in glycogen storage disease type 1a. Atherosclerosis, 110(1), 95-100. (Pubitemid 24312432)
51. Kawagoe, S; Higuchi, T; Meng, X. L; Shimada, Y; Shimizu, H; Hirayama, R; et al. (2011). Generation of induced pluripotent stem (iPS) cells derived from a murine model of Pompe disease and differentiation of Pompe-iPS cells into skeletal muscle cells. Molecular Genetics and Metabolism, 104(1-2), 123-128. doi: 10.1016/j.ymgme.2011.05.020.
52. Luptak, I; Shen, M; He, H; Hirshman, M. F; Musi, N; Goodyear, L. J; et al. (2007). Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. The Journal of Clinical Investigation, 117(5), 1432-1439. doi: 10.1172/JCI30658. (Pubitemid 46718431)
53. Arad, M; Seidman, C. E; & Seidman, J. G. (2007). AMP-activated protein kinase in the heart: role during health and disease. Circulation Research, 100(4), 474-488. doi: 10.1161/01.RES.0000258446.23525.37. (Pubitemid 46673257)
54. Kahn, B. B; Alquier, T; Carling, D; & Hardie, D. G. (2005). AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metabolism, 1(1), 15-25. doi: 10.1016/j.cmet.2004.12.003. (Pubitemid 43960587)
55. Schweiger, M; Lass, A; Zimmermann, R; Eichmann, T. O; & Zechner, R. (2009). Neutral lipid storage disease: genetic disorders caused by mutations in adipose triglyceride lipase/PNPLA2 or CGI-58/ABHD5. American Journal of Physiology, Endocrinology and Metabolism, 297(2), E289-E296. doi: 10.1152/ajpendo.00099.2009.
56. Chanarin, I; Patel, A; Slavin, G; Wills, E. J; Andrews, T. M; & Stewart, G. (1975). Neutral-lipid storage disease: a new disorder of lipid metabolism. British Medical Journal, 1(5957), 553-555.
57. Dorfman, M. L; Hershko, C; Eisenberg, S; & Sagher, F. (1974). Ichthyosiform dermatosis with systemic lipidosis. Archives of Dermatology, 110(2), 261-266.
58. Igal, R. A; Rhoads, J. M; & Coleman, R. A. (1997). Neutral lipid storage disease with fatty liver and cholestasis. Journal of Pediatric Gastroenterology and Nutrition, 25(5), 541-547. (Pubitemid 27463293)
59. Lefevre, C; Jobard, F; Caux, F; Bouadjar, B; Karaduman, A; Heilig, R; et al. (2001). Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. American Journal of Human Genetics, 69(5), 1002-1012. doi: 10.1086/324121. (Pubitemid 33015815)
60. Lass, A; Zimmermann, R; Haemmerle, G; Riederer, M; Schoiswohl, G; Schweiger, M; et al. (2006). Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman Syndrome. Cell Metabolism, 3(5), 309-319. doi: 10.1016/j.cmet.2006.03.005.
61. Zimmermann, R; Strauss, J. G; Haemmerle, G; Schoiswohl, G; Birner-Gruenberger, R; Riederer, M; et al. (2004). Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science, 306(5700), 1383-1386. doi: 10.1126/science.1100747. (Pubitemid 39532517)
62. Villena, J. A; Roy, S; Sarkadi-Nagy, E; Kim, K. H; & Sul, H. S. (2004). Desnutrin, an adipocyte gene encoding a novel patatin domain-containing protein, is induced by fasting and glucocorticoids: ectopic expression of desnutrin increases triglyceride hydrolysis. The Journal of Biological Chemistry, 279(45), 47066-47075. doi: 10.1074/jbc.M403855200. (Pubitemid 39518362)
63. Jenkins, C. M; Mancuso, D. J; Yan, W; Sims, H. F; Gibson, B; & Gross, R. W. (2004). Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. The Journal of Biological Chemistry, 279(47), 48968-48975. doi: 10.1074/jbc.M407841200. (Pubitemid 39625778)
64. Kershaw, E. E; Hamm, J. K; Verhagen, L. A; Peroni, O; Katic, M; & Flier, J. S. (2006). Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin. Diabetes, 55(1), 148-157. (Pubitemid 43343310)
65. Haemmerle, G; Lass, A; Zimmermann, R; Gorkiewicz, G; Meyer, C; Rozman, J; et al. (2006). Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science, 312(5774), 734-737. doi: 10.1126/science.1123965.
66. Hirano, K; Ikeda, Y; Zaima, N; Sakata, Y; & Matsumiya, G. (2008). Triglyceride deposit cardiomyovasculopathy. The New England Journal of Medicine, 359(22), 2396-2398. doi: 10.1056/NEJMc0805305.
67. Fischer, J; Lefevre, C; Morava, E; Mussini, J. M; Laforet, P; Negre-Salvayre, A; et al. (2007). The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nature Genetics, 39(1), 28-30. doi: 10.1038/ng1951. (Pubitemid 46026498)
68. Lake, A. C; Sun, Y; Li, J. L; Kim, J. E; Johnson, J. W; Li, D; et al. (2005). Expression, regulation, and triglyceride hydrolase activity of adiponutrin family members. Journal of Lipid Research, 46(11), 2477-2487. doi: 10.1194/jlr.M500290-JLR200. (Pubitemid 41532536)
69. Pinent, M; Hackl, H; Burkard, T. R; Prokesch, A; Papak, C; Scheideler, M; et al. (2008). Differential transcriptional modulation of biological processes in adipocyte triglyceride lipase and hormone-sensitive lipase-deficient mice. Genomics, 92(1), 26-32. doi: 10.1016/j.ygeno.2008.03.010. (Pubitemid 351842628)
70. Kobayashi, K; Inoguchi, T; Maeda, Y; Nakashima, N; Kuwano, A; Eto, E; et al. (2008). The lack of the C-terminal domain of adipose triglyceride lipase causes neutral lipid storage disease through impaired interactions with lipid droplets. The Journal of Clinical Endocrinology and Metabolism, 93(7), 2877-2884. doi: 10.1210/jc.2007-2247. (Pubitemid 352008564)
71. Hanna, J; Wernig, M; Markoulaki, S; Sun, C. W; Meissner, A; Cassady, J. P; et al. (2007). Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science, 318(5858), 1920-1923. doi: 10.1126/science.1152092.
72. Yusa, K; Rashid, S. T; Strick-Marchand, H; Varela, I; Liu, P. Q; Paschon, D. E; et al. (2011). Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cells. Nature, 478(7369), 391-394. doi: 10.1038/nature10424.
73. Hockemeyer, D; Soldner, F; Beard, C; Gao, Q; Mitalipova, M; DeKelver, R. C; et al. (2009). Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nature Biotechnology, 27(9), 851-857. doi: 10.1038/nbt.1562.
74. Lombardo, A; Genovese, P; Beausejour, C. M; Colleoni, S; Lee, Y. L; Kim, K. A; et al. (2007). Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nature Biotechnology, 25(11), 1298-1306. doi: 10.1038/nbt1353. (Pubitemid 350076515)